Investor Presentation
Avience Biomedicals Investor Presentation
Avience Biomedicals Limited released its H1 FY27 investor presentation ahead of an earnings conference call scheduled for November 17, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
2
Neutral
3
Bullish
9
Bearish
26
Neutral
11
Bullish
9
Investor Presentation
Q2 FY27
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
24
Neutral
8
Bullish
0
Healthcare Equipment & Supplies
Medical Equipment & Supplies
132 Cr
Low Risk
13.5
60.5
0.1
1.5
414.95
222.00
Sales CAGR
Profit CAGR
ROE
ROCE
Avience Biomedicals Ltd (AVIENCE) is currently trading at 231.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Avience Biomedicals manufactures, distributes and markets in-vitro diagnostic products, medical devices, reagents, analyzers and consumables for government and private healthcare institutions across India and selected overseas markets. Its B2B and B2G model combines manufacturing, distribution, analyzer placement and recurring consumables revenue, supported by a Noida facility and a nationwide customer network. H1 FY27 revenue rose 16.07% year-on-year to ₹31.13 crore, while PAT increased 22% to ₹5.54 crore. Profit growth exceeded revenue growth despite EBITDA margin remaining broadly stable at 26.93%, indicating operating discipline, improved product mix or other below-EBITDA efficiencies, although the presentation does not provide a detailed bridge explaining the margin movement. Manufacturing revenue grew 73.36% to ₹11.23 crore, while trading revenue declined 2.17% to ₹19.90 crore. This mix shift is strategically important because it indicates increasing contribution from the company’s own products, though trading still represented the larger portion of H1 FY27 revenue and remains material to overall performance. Export contribution increased sharply from 1.01% of FY26 revenue to 13.53% in H1 FY27. The change suggests initial international traction, but the company remains predominantly domestic and the presentation does not disclose export geography, customer concentration, order visibility or whether this higher export share is sustainable. Avience Biomedicals reports 117 CDSCO manufacturing licences and more than 200 products under regulatory process. Its proposed ₹30.18 crore automated YEIDA facility, targeted for January 2027, is intended to support biochemistry analyzers, reagents, product diversification and institutional demand, making execution and regulatory commercialization the central next-stage catalysts.
Over the past 52 weeks, Avience Biomedicals Ltd has traded between a low of ₹222.00 and a high of ₹414.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Avience Biomedicals Ltd has a market capitalization of approximately 131.53. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Avience Biomedicals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 13.48 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 131.53 Cr, Avience Biomedicals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Avience Biomedicals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Avience Biomedicals Ltd is 13.48. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Avience Biomedicals reported PAT of Rs 5.5362 crore in H1 FY27. That was 22.00% higher than Rs 4.5378 crore in H1 FY26.
Avience reports 117 CDSCO manufacturing licenses already obtained. Its portfolio summary says these licenses span four diagnostic segments and cover diagnostics, reagents, consumables and medical devices.
Avience targets January 2027 for commissioning its proposed fully automated YEIDA facility. The presentation describes this as a target date and does not report that operations have started.
The price band was ₹196 to ₹208 per share, and the IPO price was fixed at ₹208 per share.
Investor Presentation
Avience Biomedicals Limited released its H1 FY27 investor presentation ahead of an earnings conference call scheduled for November 17, 2026.
Earnings Call/Transcript
Avience Biomedicals will hold an earnings conference call on November 17, 2026, at 1:00 PM IST to discuss unaudited H1 FY27 financial results.